- Previous Close
3.3300 - Open
3.3800 - Bid 3.3100 x --
- Ask 3.3200 x --
- Day's Range
3.2800 - 3.3800 - 52 Week Range
2.2300 - 6.4300 - Volume
10,540,004 - Avg. Volume
21,742,601 - Market Cap (intraday)
3.495B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0800 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Jul 3, 2020
- 1y Target Est
--
Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. The company provides anti-tumor, anti-inflammatory, antibacterial, digestive, anti-virus, blood system, cardiovascular system, acid-base balance nutritional medicine, endocrine system drugs, tumor adjuvant medication, antifungal, and opioid receptor antagonists. Chongqing Lummy Pharmaceutical Co., Ltd. was founded in 1999 and is headquartered in Chongqing, China.
www.cqlummy.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 300006.SZ
View MorePerformance Overview: 300006.SZ
Trailing total returns as of 4/18/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 300006.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 300006.SZ
View MoreValuation Measures
Market Cap
3.50B
Enterprise Value
2.92B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.39
Price/Book (mrq)
1.86
Enterprise Value/Revenue
3.67
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-11.04%
Return on Assets (ttm)
-1.32%
Return on Equity (ttm)
-4.00%
Revenue (ttm)
795.6M
Net Income Avi to Common (ttm)
-87.8M
Diluted EPS (ttm)
-0.0800
Balance Sheet and Cash Flow
Total Cash (mrq)
1.07B
Total Debt/Equity (mrq)
26.26%
Levered Free Cash Flow (ttm)
87.15M